pbo-5 Antibody
Description
Definition of PBO in Clinical Trials
PBO universally denotes placebo in clinical research, serving as a control arm to evaluate the efficacy and safety of investigational drugs, including monoclonal antibodies . For example:
-
In a Phase 2a trial for Sjögren’s syndrome, MEDI5872 (an anti-ICOS ligand antibody) was compared to PBO, with PBO patients showing no significant reduction in rheumatoid factor levels .
-
A Phase 3 study of pegloticase + methotrexate (MTX) versus pegloticase + PBO demonstrated a 29.1% higher response rate in the MTX group .
Potential Misinterpretation of "pbo-5"
The suffix "-5" may refer to:
-
Study cohorts: Some trials label treatment arms numerically (e.g., PBO-1, PBO-2) to distinguish dosage groups .
-
Trial identifiers: Protocol numbers or internal codes (e.g., NCT02334306 for MEDI5872 , NCT04968912 for nipocalimab ).
Antibody Mechanisms and Clinical Outcomes
While "pbo-5 Antibody" remains unidentified, recent studies highlight antibodies targeting specific pathways:
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
